Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer
NCT07096180
Summary
The aim of this study is to investigate the intervention of traditional Chinese medicine (TCM) in managing the side effects experienced by breast cancer patients undergoing conventional Western medical treatments, such as blood cell decline, nausea, vomiting, gastrointestinal discomfort, and overall quality of life. The study aims to establish a long-term clinical enrollment criteria and process for TCM adjuvant therapy in breast cancer. The research design will utilize a prospective cohort study and real-world cross-sectional observational research method to obtain clinical data and survival status of the patients.
Eligibility
Inclusion Criteria: * A. Aged 18 years or above. * B. Female patients diagnosed with primary breast cancer and receiving Western medical treatment. The included breast cancer diagnosis codes based on ICD-9 are 174 to 179. Exclusion Criteria: * A. Patients with a prior diagnosis of other malignant tumors before being diagnosed with primary breast cancer. * B. Patients with primary breast cancer who have not received Western medical treatment, meaning they have not undergone surgical resection, radiation therapy, chemotherapy, or targeted therapy.. * C. After taking Chinese medicine, those who have uncomfortable symptoms or whose behavior affects Western medicine treatment should withdraw from the trial.
Conditions2
Interventions1
Related trials
- CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
- Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting — University Hospital, Strasbourg, France
- DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases — Tehran University of Medical Sciences
- Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars — University Hospital, Linkoeping
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. — National Cancer Institute, Naples
- Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer — Chinese PLA General Hospital
- Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers — Immunocore Ltd
- Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not — First Affiliated Hospital of Zhejiang University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07096180